Cite

HARVARD Citation

    Nachman, S. et al. (2018). Safety and efficacy at 240 weeks of different raltegravir formulations in children with HIV-1: a phase 1/2 open label, non-randomised, multicentre trial. Lancet. 5 (12), pp. e715-e722. [Online]. 
  
Back to record